Zoetis narrows 2026 revenue outlook and raises adjusted EPS guidance
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Zoetis (ZTS) Q3 2026 MANAGEMENT VIEW * "Today, we reported our third quarter results with revenue and adjusted net income both declining in line with our expectations." (CEO & Director Kristin Peck) * "While challenging dynamics are continuing, we are…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralA guidance update from a large animal health company, with mixed signals on clinic demand.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Zoetis expects 2026 revenue of $9.22B to $9.32B and adjusted EPS of $6.25 to $6.35.
- 02Management reports U.S. clinic visits down 3% year to date.
- 03U.S. approval of long-acting Cytopoint is expected in Q4, and Simparica Duo by year-end.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets